P/E ratio for Dr. Reddy's (RDY)
P/E ratio as of May 2023 (TTM): 22.9
According to Dr. Reddy's's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 22.9477. At the end of 2021 the company had a P/E ratio of 28.5.
P/E ratio history for Dr. Reddy's from 2002 to 2022
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2021 | 28.5 | -31.57% |
| 2020 | 41.7 | 44.77% |
| 2019 | 28.8 | 15.86% |
| 2018 | 24.8 | -38.84% |
| 2017 | 40.6 | -22.84% |
| 2016 | 52.6 | 151.93% |
| 2015 | 20.9 | -13.41% |
| 2014 | 24.1 | 29.94% |
| 2013 | 18.6 | -9.9% |
| 2012 | 20.6 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Novartis NVS | 29.4 | 28.27% | 🇨🇭 Switzerland |
 Pfizer PFE | 7.14 | -68.86% | 🇺🇸 USA |
 Sanofi SNY | 17.7 | -22.73% | 🇫🇷 France |
 GlaxoSmithKline GSK | 4.22 | -81.63% | 🇬🇧 UK |
 Teva Pharmaceutical Industries TEVA | -3.40 | -114.82% | 🇮🇱 Israel |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.